Carlos L. Arteaga
Affiliations: | Vanderbilt University, Nashville, TN |
Area:
Cell Biology, Oncology, Molecular BiologyGoogle:
"Carlos Arteaga"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Xu Y, Wang Z, Sjöström M, et al. (2023) ZNF397 Loss Triggers TET2-driven Epigenetic Rewiring, Lineage Plasticity, and AR-targeted Therapy Resistance in AR-dependent Cancers. Biorxiv : the Preprint Server For Biology |
Lin CC, Chang TC, Wang Y, et al. (2023) Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer. Research Square |
Marin A, Mamun AA, Patel H, et al. (2023) Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer. Cancer Research |
Liu S, Xie SM, Liu W, et al. (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Breast Cancer Research : Bcr. 25: 62 |
Kumar A, Ramani V, Bharti V, et al. (2023) Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses. Journal For Immunotherapy of Cancer. 11 |
Clark AS, Hong F, Finn RS, et al. (2023) Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF7 |
Liu S, Xie SM, Liu W, et al. (2023) Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. Research Square |
Gonzalez-Ericsson PI, Servetto A, Formisano L, et al. (2022) FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer. Applied Immunohistochemistry & Molecular Morphology : Aimm |
Bedard PL, Li S, Wisinski KB, et al. (2022) Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2-Activating Mutations: Results From the National Cancer Institute-Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B. Jco Precision Oncology. 6: e2200165 |
Hanna A, Nixon MJ, Estrada MV, et al. (2022) Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer. Breast Cancer Research : Bcr. 24: 51 |